The term TC 21 Inhibitors refers to a distinct chemical class characterized by its ability to modulate a specific biological pathway associated with cell growth and proliferation. At its core, TC 21, also known as Rheb (Ras homolog enriched in brain), is a small GTPase that plays a pivotal role in the regulation of the mTOR (mechanistic target of rapamycin) signaling pathway. This intricate signaling cascade is fundamental to cellular processes such as protein synthesis, autophagy, and cell growth. The inhibitors belonging to the TC 21 class specifically target the activity of TC 21 or its downstream effectors, aiming to disrupt the finely tuned balance of cellular responses orchestrated by the mTOR pathway.
TC 21 Inhibitors are meticulously designed compounds that interact with the molecular components of the TC 21 signaling pathway, influencing the dynamic equilibrium between active and inactive states. The intricate interplay between TC 21 and mTOR serves as a linchpin in cellular homeostasis, and the inhibitors in this class act as precision tools to modulate this intricate machinery. Researchers scrutinize the structural and functional aspects of TC 21 Inhibitors to gain insights into their mechanism of action, seeking to unravel the complex web of molecular events that govern cellular fate.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Inhibits HMG-CoA reductase, reducing the biosynthesis of isoprenoids used in the prenylation of Ras proteins, thereby impacting RRAS2 function. | ||||||
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $61.00 $82.00 | 15 | |
Mimics farnesyl cysteine, competitively inhibiting the interaction of Ras proteins with their effectors and could similarly affect RRAS2. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Non-steroidal anti-inflammatory drug that has been shown to disrupt Ras signaling by inhibiting Ras-Raf interaction, which may extend to RRAS2. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
A farnesyltransferase inhibitor that may prevent the farnesylation of RRAS2, thus impairing its function. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
A farnesyltransferase inhibitor that could block RRAS2 farnesylation and subsequent localization to the plasma membrane. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
A farnesyltransferase inhibitor that can interfere with RRAS2 processing and membrane association. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
A geranylgeranyltransferase inhibitor that can disrupt the localization and function of geranylgeranylated proteins, which may include RRAS2. | ||||||